Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Sauce Labs Becomes the First Dedicated Software Quality Platform to Achieve ISO 42001 Certification for Responsible AI30.6.2026 17:00:00 CEST | Press release
As AI takes on decisions that used to belong to engineers, the world's largest continuous testing cloud joins the small group of companies in any industry independently certified to govern AI responsibly SAN FRANCISCO, CA / ACCESS Newswire / June 30, 2026 / Sauce Labs, the world's largest continuous testing cloud, today announced it has achieved ISO/IEC 42001 certification, the first international standard for the responsible management of artificial intelligence. The certification covers Sauce AI, including Sauce AI for Insights and Sauce AI for Test Authoring, and makes Sauce Labs the first company dedicated to software quality to bring its AI capabilities under a fully certified AI Management System. Only a small number of companies worldwide, in any industry, have cleared this bar. Software is being written faster than at any point in history, and AI is now making quality decisions that used to belong to engineers. That shift has changed the question enterprise buyers ask. It is no
Human-Robot Collaboration Takes Center Stage at Prestigious Logistics Award30.6.2026 15:00:00 CEST | Press release
Denmark's The Mobile Robot Company wins IFOY Industrial Truck of the Year 2026 with a self-driving pallet jack built to empower warehouse operators rather than replace them. STUTTGART, DE / ACCESS Newswire / June 30, 2026 / In warehouses and factories, much of the work that keeps goods moving is still measured in footsteps. Operators walk the same routes, push the same loads, and repeat the same transport tasks hour after hour. For years, automation has promised to remove that work, but often with a catch: complex projects, fixed infrastructure, long integrations, and systems that assume people should be designed out of the process. At this year's IFOY AWARD, one of intralogistics' most respected technology prizes, the Industrial Truck of the Year award went to a different idea. The Mobile Robot Company, a young Danish robotics startup, won the 2026 title for the J1600 self-driving pallet jack, a robot designed not to replace the warehouse operator, but to work under the operator's dir
RAK ICC Launches New Business Centre in Ras Al Khaimah30.6.2026 14:00:00 CEST | Press release
New initiative creates a dedicated hub for private wealth advisors, family offices and international families in the UAE RAS AL KHAIMAH CITY, AE / ACCESS Newswire / June 30, 2026 / RAK International Corporate Centre (RAK ICC), one of the UAE's leading international corporate registries for private wealth and cross-border structuring, today announced the launch of its new Business Centre in Ras Al Khaimah - a new destination designed specifically for advisors, entrepreneurs, family offices and international families seeking a professional and lasting presence in the UAE. Officially opening on 1 July 2026, the Business Centre reflects RAK ICC's broader vision of creating a more connected and relationship-driven private wealth ecosystem within the emirate. Located within RAK ICC's headquarters, the centre offers convenient access to major transport and commercial hubs, situated approximately 45 minutes from Dubai International Airport and within proximity to Ras Al Khaimah's key business
Affiliate of Pacific Avenue Capital Partners Completes Acquisition of ESE World from Amcor30.6.2026 13:50:00 CEST | Press release
PARIS, FR / ACCESS Newswire / June 30, 2026 / Pacific Avenue Capital Partners ("Pacific Avenue"), a global private equity firm focused on corporate carve-outs and other complex transactions in the middle market, today announced that an affiliate of Pacific Avenue has completed the acquisition of ESE World (the "Company" or "ESE") from Amcor, one of the world's leading packaging companies. ESE is Europe's leading manufacturer of waste and recycling container systems, serving municipalities and businesses globally. The Company produces mobile waste containers, collection banks, hazardous materials containers, and public furnishing solutions from three manufacturing facilities in Germany (Neuruppin and Olpe) and France (Crissey), generating approximately €300m in revenues. Having completed the carve-out from Amcor, ESE will operate as an independent company with the focus and resources to pursue its next phase of growth. Pacific Avenue will work in close partnership with the management te
Multi-Billion-Dollar Global Sports Brand U.S. Polo Assn. Earns Global Awards and Recognitions Across Business, Sport, and Content Categories30.6.2026 13:00:00 CEST | Press release
WEST PALM BEACH, FL / ACCESS Newswire / June 30, 2026 / U.S. Polo Assn.®, the official sports brand of the United States Polo Association (USPA), continues to gain global momentum in 2026, earning a series of high-profile honors and recognitions that reflect the brand's expanding footprint, deepening consumer trust, and growing influence in sports-driven content and storytelling. Among U.S. Polo Assn.'s top recognitions this year, the global, multi-billion-dollar brand was honored at the 11th Annual 2026 Globee Awards for Achievement with Gold for the "Global Expansion" category and Silver for the "Brand Development" category. These awards highlight U.S. Polo Assn.'s ability to scale its authentic, sport-inspired brand across more than 190 countries while building a consistent and relevant brand in diverse markets worldwide. The recognition follows a record-setting $2.7 billion in global retail sales in 2025, reinforcing the brand's continued upward trajectory. Trust and consumer credi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom